Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Interaction of Buprenorphine and Fentanyl
NCT03747341Phase 1Completed
- Sponsor
- Indivior
- Start
- Mar 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of buprenorphine extended-release injection in opioid-induced respiratory depression (OIRD) (7 arms), sponsored by Indivior. Primary endpoint: Changes in peak ventilatory depression at 6 hours. Started Mar 2018; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NCT03747341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747341.